📊 VTGN Key Takeaways
Is Vistagen Therapeutics, Inc. (VTGN) a Good Investment?
Vistagen is a pre-commercial biotech company facing critical cash runway pressure with only ~5.5 months of cash remaining at current $66.4M annual burn rate, offsetting improvements in loss trajectory. While revenue grew 161% YoY and net losses declined 35.5% YoY, absolute losses of $72.1M on just $1.3M in revenue indicate the company remains years away from sustainable profitability without major clinical or financing catalysts.
Vistagen Therapeutics, Inc. Key Strengths (VTGN)
- Net losses improved 35.5% YoY, indicating operational leverage or cost controls gaining traction
- Revenue growth of 161% YoY demonstrates emerging commercial traction despite tiny absolute base
- Zero long-term debt with healthy balance sheet structure ($35.5M equity vs $13.0M liabilities)
VTGN Stock Risks: Vistagen Therapeutics, Inc. Investment Risks
- Critical cash runway of only ~5.5 months at current $66.4M annual burn rate necessitates near-term capital raise
- Massive operating losses (-$72.1M) on minimal revenue ($1.3M) indicates massive development stage risk
- Severe profitability gap with negative operating margin of -5683% and negative FCF margin of -5235%
Key Metrics to Watch
- Monthly cash burn rate and updated runway projections
- Clinical trial progression and regulatory milestone achievements
- Revenue growth trajectory and path to gross margin expansion
Vistagen Therapeutics, Inc. (VTGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.67x current ratio provides a solid financial cushion.
VTGN Profit Margin, ROE & Profitability Analysis
VTGN vs Healthcare Sector: How Vistagen Therapeutics, Inc. Compares
How Vistagen Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vistagen Therapeutics, Inc. Stock Overvalued? VTGN Valuation Analysis 2026
Based on fundamental analysis, Vistagen Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vistagen Therapeutics, Inc. Balance Sheet: VTGN Debt, Cash & Liquidity
VTGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vistagen Therapeutics, Inc.'s revenue has grown significantly by 14% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.67 indicates the company is currently unprofitable.
VTGN Revenue Growth, EPS Growth & YoY Performance
VTGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $234.0K | -$10.7M | $-0.45 |
| Q2 2026 | $183.0K | -$10.7M | $-0.42 |
| Q1 2026 | $84.0K | -$10.7M | $-0.35 |
| Q3 2025 | $234.0K | -$6.4M | $-0.22 |
| Q2 2025 | $183.0K | -$6.6M | $-0.42 |
| Q1 2025 | $84.0K | -$6.9M | $-0.35 |
| Q3 2024 | $411.4K | -$6.3M | N/A |
| Q2 2024 | $277.7K | -$6.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vistagen Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
VTGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vistagen Therapeutics, Inc. (CIK: 0001411685)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VTGN
What is the AI rating for VTGN?
Vistagen Therapeutics, Inc. (VTGN) has an AI grade of D with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VTGN's key strengths?
Claude: Net losses improved 35.5% YoY, indicating operational leverage or cost controls gaining traction. Revenue growth of 161% YoY demonstrates emerging commercial traction despite tiny absolute base.
What are the risks of investing in VTGN?
Claude: Critical cash runway of only ~5.5 months at current $66.4M annual burn rate necessitates near-term capital raise. Massive operating losses (-$72.1M) on minimal revenue ($1.3M) indicates massive development stage risk.
What is VTGN's revenue and growth?
Vistagen Therapeutics, Inc. reported revenue of $1.3M.
Does VTGN pay dividends?
Vistagen Therapeutics, Inc. does not currently pay dividends.
Where can I find VTGN SEC filings?
Official SEC filings for Vistagen Therapeutics, Inc. (CIK: 0001411685) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VTGN's EPS?
Vistagen Therapeutics, Inc. has a diluted EPS of $-1.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VTGN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Vistagen Therapeutics, Inc. has a D grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VTGN stock overvalued or undervalued?
Valuation metrics for VTGN: ROE of -196.2% (sector avg: 15%), net margin of -5,491.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VTGN's AI grade for 2026?
Our dual AI analysis gives Vistagen Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VTGN's free cash flow?
Vistagen Therapeutics, Inc.'s operating cash flow is $-66.4M, with capital expenditures of $0.0. FCF margin is -5,235.3%.
How does VTGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,491.3% (avg: 12%), ROE -196.2% (avg: 15%), current ratio 3.67 (avg: 2).